JP2025506487A - Rhoキナーゼを阻害する組成物及び方法 - Google Patents

Rhoキナーゼを阻害する組成物及び方法 Download PDF

Info

Publication number
JP2025506487A
JP2025506487A JP2024547502A JP2024547502A JP2025506487A JP 2025506487 A JP2025506487 A JP 2025506487A JP 2024547502 A JP2024547502 A JP 2024547502A JP 2024547502 A JP2024547502 A JP 2024547502A JP 2025506487 A JP2025506487 A JP 2025506487A
Authority
JP
Japan
Prior art keywords
cancer
larazotide
subject
derivative
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547502A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506487A5 (cg-RX-API-DMAC7.html
Inventor
ヨンゴン ジン
ニール バラク
ジェイン キム
Original Assignee
インタールード バイオファオーマ カンパニー
ユニバーシティ オブ メリーランド, カレッジ パーク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インタールード バイオファオーマ カンパニー, ユニバーシティ オブ メリーランド, カレッジ パーク filed Critical インタールード バイオファオーマ カンパニー
Publication of JP2025506487A publication Critical patent/JP2025506487A/ja
Publication of JP2025506487A5 publication Critical patent/JP2025506487A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024547502A 2022-02-09 2023-02-09 Rhoキナーゼを阻害する組成物及び方法 Pending JP2025506487A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263308330P 2022-02-09 2022-02-09
US63/308,330 2022-02-09
PCT/US2023/062247 WO2023154770A1 (en) 2022-02-09 2023-02-09 Compositions and methods for inhibiting rho kinase

Publications (2)

Publication Number Publication Date
JP2025506487A true JP2025506487A (ja) 2025-03-11
JP2025506487A5 JP2025506487A5 (cg-RX-API-DMAC7.html) 2026-02-17

Family

ID=87565095

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547502A Pending JP2025506487A (ja) 2022-02-09 2023-02-09 Rhoキナーゼを阻害する組成物及び方法

Country Status (6)

Country Link
US (1) US20250144166A1 (cg-RX-API-DMAC7.html)
EP (1) EP4475867A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025506487A (cg-RX-API-DMAC7.html)
CN (1) CN119730867A (cg-RX-API-DMAC7.html)
CA (1) CA3243960A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023154770A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118873629B (zh) * 2024-09-27 2024-12-10 北京大学口腔医学院 醋酸拉唑肽在制备促进成骨药物中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009047532A2 (en) * 2007-10-12 2009-04-16 Cancer Research Technology Limited Cancer susceptibility loci
WO2009132050A2 (en) * 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
JP2020507626A (ja) * 2017-02-10 2020-03-12 イノベイト バイオファーマシューティカルズ インコーポレイテッド 腸上皮の透過性と関連する疾患を治療する組成物及び方法
WO2019183036A1 (en) * 2018-03-19 2019-09-26 Innovate Biopharmaceuticals, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
KR20220049005A (ko) * 2019-08-16 2022-04-20 9 미터스 바이오파마, 인코포레이티드 라라조타이드 제형
AU2021255955A1 (en) * 2020-04-15 2022-11-10 Interlude Biopharma Co. Larazotide derivatives comprising d-amino acids

Also Published As

Publication number Publication date
WO2023154770A1 (en) 2023-08-17
EP4475867A1 (en) 2024-12-18
CA3243960A1 (en) 2023-08-17
EP4475867A4 (en) 2026-02-18
US20250144166A1 (en) 2025-05-08
CN119730867A (zh) 2025-03-28

Similar Documents

Publication Publication Date Title
AU2018352221B2 (en) Peptides and nanoparticles for intracellular delivery of mRNA
Bu et al. PERK integrates oncogenic signaling and cell survival during cancer development
ES2459018T3 (es) Formulaciones de efectores de la unión estrecha
CN106661094B (zh) 骨形态发生蛋白的治疗用途
EP3442541A1 (en) Methods for treating cancer and inhibiting graft rejection
WO2023114984A1 (en) Tead inhibitors and uses thereof
CN112543809A (zh) 包含C/EBPα saRNA的组合疗法
JP2022521299A5 (cg-RX-API-DMAC7.html)
EP2895173B1 (en) Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
US20250144166A1 (en) Compositions and methods for inhibiting rho kinase
Parrasia et al. Targeting pancreatic ductal adenocarcinoma (PDAC)
JP7583448B2 (ja) 抗腫瘍アレナウイルスおよびアレナウイルス変異体を生産するための方法
MG Saez Treatment directed to signalling molecules in patients with advanced differentiated thyroid cancer
JP7525408B2 (ja) ペプチドを用いる併用療法
CN116390757A (zh) 用于治疗肿瘤的药物组合物
CN115956078A (zh) Akt3调节剂及其使用方法
CN108601850A (zh) 抗癌和抗炎症治疗及其方法
CN111821458A (zh) 一种用于非小细胞肺癌治疗的药物组合物
JP5393691B2 (ja) 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬(TpoRA)
Dayanc et al. Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is
Dayanc et al. Challenges in First-Line Osimertinib Therapy in EGFR-Mutant Non-small Cell Lung Cancer: Acquired Resistance Is the Issue
CN118217382A (zh) 使用麦胶蛋白肽治疗癌症的套件和方法
WO2020252453A1 (en) Membrane attack complexes and uses thereof
JP7598660B2 (ja) フラジェリン由来のtlr5アゴニストを有効成分として含む抗がん剤組成物
Zhao et al. Zolbetuximab combined with chemotherapy in a patient with CLDN18. 2-positive advanced gastric cancer undergoing hemodialysis: a case report

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20250313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260206